{"id":56530,"date":"2021-12-14T21:04:00","date_gmt":"2021-12-14T14:04:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021121421040056530"},"modified":"2021-12-15T17:55:15","modified_gmt":"2021-12-15T09:55:15","slug":"%e3%80%90%e7%9b%b4%e5%87%bb2021-ash%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%85%ac%e5%b8%83bcl-2%e9%80%89%e6%8b%a9%e6%80%a7%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%a4%e9%a1%b9%e7%a0%94","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021121421040056530","title":{"rendered":"\u3010\u76f4\u51fb2021 ASH\u3011\u4e9a\u76db\u533b\u836f\u516c\u5e03Bcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u4e24\u9879\u7814\u7a76\u8fdb\u5c55\uff0c\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u5448\u73b0CR"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e7412\u670814\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5df2\u5728\u7b2c63\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e09\u4e2a\u5728\u7814\u65b0\u836f\uff08\u8010\u7acb\u514b®<\/sup>\u3001APG-2575\u3001APG-1252\uff09\u7684\u516d\u9879\u7814\u7a76\u8fdb\u5c55\u3002<\/p>\n

\n<\/p><\/div>\n

\u5176\u4e2d\uff0c\u516c\u53f8\u7ec6\u80de\u51cb\u4ea1\u54c1\u79cd\u5728\u7814\u539f\u521b1\u7c7b\u65b0\u836fBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u53cc\u9776\u70b9\u6291\u5236\u5242pelcitoclax\uff08APG-1252\uff09\u4ee5\u58c1\u62a5\u5c55\u793a\u5f62\u5f0f\uff0c\u5206\u522b\u516c\u5e03\u4e86\u4e24\u9879\u4e34\u5e8a\u6570\u636e\u548c\u4e00\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u7ed3\u679c\uff08\u8010\u7acb\u514b®<\/sup>\u53e3\u5934\u62a5\u544a\u6570\u636e\u53c2\u89c1\u540c\u671f\u53d1\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u95fb\u7a3f\uff09\u3002<\/p>\n

\u503c\u5f97\u5173\u6ce8\u7684\u662f\uff0cAPG-2575\u6cbb\u7597\u8840\u6db2\u80bf\u7624\u7684\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7eI\u671f\u5355\u836f\u7814\u7a76\u7684\u6570\u636e\u663e\u793a\uff0cAPG-2575\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u65e0\u4efb\u4f55\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\uff08TLS\uff09\u53d1\u751f\u3002\u622a\u6b62\u6570\u636e\u5206\u6790\u622a\u70b9\uff082021\u5e747\u670827\u65e5\uff09\uff0c\u572825\u4f8b\u81f3\u5c11\u5b8c\u6210\u4e86\u4e00\u6b21\u80bf\u7624\u8bc4\u4f30\u7684\u60a3\u8005\u4e2d\uff08\u5171\u5165\u7ec431\u4f8b\uff09\uff0c\u67099\u4f8b\u83b7\u5f97\u4e86\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u6216\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\u3002\u63a5\u53d7200mg\u53ca\u4ee5\u4e0a\u5242\u91cf\u6cbb\u7597\u76846\u4f8b\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08CLL\uff09\u53d7\u8bd5\u8005\u5747\u83b7\u76ca\uff0c\u4e3a1\u4f8bCR\u548c5\u4f8bPR\u3002<\/p>\n

APG-2575\u6cbb\u7597\u8840\u6db2\u80bf\u7624I\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u8005\u3001\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u8840\u6db2\u75c5\u533b\u9662\uff08\u8840\u6db2\u5b66\u7814\u7a76\u6240\uff09\u526f\u6240\u9662\u957f\u738b\u5efa\u7965\u6559\u6388\u8868\u793a\uff1a\u201cAPG-2575\u6b64\u6b21\u516c\u5e03\u7684\u4e2d\u56fd\u4e34\u5e8a\u6570\u636e\u4ee4\u4eba\u632f\u594b\uff0c\u7279\u522b\u662f\u63a5\u53d7200mg\u53ca\u4ee5\u4e0a\u5242\u91cf\u6cbb\u7597\u7684CLL\u60a3\u8005\u5747\u83b7\u76ca\uff0c\u548c\u56fd\u5916\u83b7\u6279\u4e0a\u5e02\u7684\u540c\u7c7b\u836f\u7269\u76f8\u6bd4\uff1a\u7597\u6548\u81f3\u5c11\u76f8\u5f53\uff0c\u800c\u5728TLS\u548c\u8840\u6db2\u5b66\u6bd2\u6027\u7b49\u5b89\u5168\u6027\u65b9\u9762\u663e\u793a\u51fa\u8f83\u4e3a\u660e\u663e\u7684\u4f18\u52bf\uff0c\u540c\u65f6\u7ed9\u836f\u65b9\u6848\u66f4\u4e3a\u7b80\u4fbf\u3002\u6211\u4eec\u671f\u5f85\u540e\u7eed\u66f4\u591a\u7684\u4e34\u5e8a\u6570\u636e\u9a8c\u8bc1\uff0c\u4e3a\u60a3\u8005\u63d0\u4f9b\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u3002\u201d<\/p>\n

\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u8868\u793a\uff1a\u201c\u516c\u53f8\u7ec6\u80de\u51cb\u4ea1\u91cd\u8981\u54c1\u79cdAPG-2575\u548cAPG-1252\u5728ASH\u5e74\u4f1a\u4e0a\u83b7\u5f97\u4e86\u9996\u6b21\u4eae\u76f8\uff0c\u662f\u4e9a\u76db\u5728\u7ee7\u8010\u7acb\u514b®<\/sup>\u4e4b\u540e\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u5b9e\u529b\u7684\u8fdb\u4e00\u6b65\u5c55\u793a\uff0c\u4e5f\u5145\u5206\u663e\u793a\u4e86\u56fd\u9645\u8840\u6db2\u5b66\u754c\u5bf9\u8fd9\u4e24\u9879\u5728\u7814\u54c1\u79cd\u4ef7\u503c\u4e0e\u4e34\u5e8a\u4f18\u52bf\u7684\u5173\u6ce8\u548c\u8ba4\u53ef\u3002\u672c\u6b21ASH\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u826f\u597d\u6570\u636e\u8ba9\u6211\u4eec\u5907\u53d7\u9f13\u821e\uff0c\u7279\u522b\u662fAPG-2575\u7684\u6570\u636e\u8bc1\u660e\u4e86\u5176\u5728\u5b89\u5168\u6027\u4e0e\u7597\u6548\u65b9\u9762\u7684\u6f5c\u529b\u3002APG-2575\u662f\u9996\u4e2a\u5728\u4e2d\u56fd\u8fdb\u5165\u4e34\u5e8a\u9636\u6bb5\u3001\u672c\u571f\u7814\u53d1\u7684Bcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\uff0c\u5177\u6709best-in-class\u7684\u6f5c\u529b\u3002\u6211\u4eec\u5c06\u52a0\u901f\u63a8\u8fdb\u8be5\u54c1\u79cd\u5728\u8840\u6db2\u80bf\u7624\u65b9\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u671f\u5f85\u80fd\u65e9\u65e5\u60e0\u53ca\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u3002\u201d<\/p>\n

APG-2575\u57282021 ASH\u5e74\u4f1a\u5c55\u793a\u7684\u4e24\u9879\u7814\u7a76\u6570\u636e\u5982\u4e0b\uff1a<\/p>\n

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R\/R) Hematologic Malignancies (HMs)<\/b><\/p>\n

\u65b0\u578b<\/b>BCL-2<\/b>\u6291\u5236\u5242<\/b>lisaftoclax<\/b>\uff08<\/b>APG-2575<\/b>\uff09\u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u80bf\u7624\uff08<\/b>HMs<\/b>\uff09\u7684\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\uff08<\/b>PK<\/b>\uff09\u3001\u836f\u6548\u52a8\u529b\u5b66\uff08<\/b>PD<\/b>\uff09\u7684<\/b>I<\/b>\u671f\u4e34\u5e8a\u7814\u7a76<\/b><\/p>\n

    \n
  • \u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a <\/li>\n
  • \u6458\u8981\u7f16\u53f7\uff1a3730 <\/li>\n
  • \u5206\u4f1a\u573a\uff1a642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III \uff08\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u548c\u6d41\u884c\u75c5\u5b66\u8fdb\u5c55\uff1a\u58c1\u62a5\u5c55\u793aIII\uff09 <\/li>\n
  • \u6838\u5fc3\u8981\u70b9 <\/li>\n
      \n
    • \u8fd9\u662f\u4e00\u9879\u5728\u4e2d\u56fd\u8fdb\u884c\u7684\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027I\u671f\u5355\u836f\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30lisaftoclax\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u6210\u4ebaCLL\u6216\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u7684\u5b89\u5168\u6027\uff08\u5305\u62ec\u5242\u91cf\u9650\u5236\u6bd2\u6027[DLT]\u548c\u6700\u5927\u8010\u53d7\u5242\u91cf[MTD]\uff09\u3001PK\u3001PD\u4ee5\u53ca\u521d\u6b65\u7597\u6548\u3002 <\/li>\n
    • \u622a\u6b622021\u5e747\u670827\u65e5\uff0c\u672c\u7814\u7a76\u5165\u7ec4\u768431\u4f8b\u53d7\u8bd5\u8005\u5206\u522b\u63a5\u53d7\u4e86lisaftoclax\u6cbb\u7597\uff0c\u5242\u91cf\u6c34\u5e73\u4ece\u6700\u4f4e20mg\u81f3\u6700\u9ad8800mg\uff0c\u63a5\u53d7\u6cbb\u7597\u7684\u4e2d\u4f4d\u5468\u671f\u6570\u4e3a4\u4e2a\u5468\u671f\uff081-14\uff09\uff0c\u5171\u5305\u62ec9\u4f8bCLL\/SLL\u30016\u4f8b\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\uff08MCL\uff09\u30013\u4f8b\u8fb9\u7f18\u533a\u6dcb\u5df4\u7624\uff08MZL\uff09\u30018\u4f8b\u6ee4\u6ce1\u6dcb\u5df4\u7624\u30012\u4f8b\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u30011\u4f8b\u6dcb\u5df4\u6d46\u7ec6\u80de\u6837\u6dcb\u5df4\u7624\/\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7\uff08LPL\/WM\uff09\u30011\u4f8b\u8840\u7ba1\u514d\u75ab\u6bcd\u7ec6\u80de\u6027\u6dcb\u5df4\u7624\uff08AITL\uff09\u548c1\u4f8b\u8548\u6837\u9709\u83cc\u75c5\uff08MF\uff09\u3002\u65e0DLT\u53d1\u751f\uff0c\u65e0\u5b9e\u9a8c\u5ba4\u548c\u4e34\u5e8aTLS\u53d1\u751f\uff0c\u672a\u8fbeMTD\u3002II\u671f\u63a8\u8350\u5242\u91cf\uff08RP2D\uff09\u4e3a600mg\u3002 <\/li>\n
    • lisaftoclax\u7684\u8010\u53d7\u6027\u826f\u597d\u300228\u4f8b\u53d7\u8bd5\u8005\u4e2d\u89c2\u5bdf\u5230\u7684\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u5927\u591a\u6570\u4e3a1-2\u7ea7\u3002\u5e38\u89c1TRAE\uff08\uff1e10%\uff09\u5305\u62ec\u8840\u5c0f\u677f\u8ba1\u6570\u964d\u4f4e\uff0834.4%\uff09\u3001\u8d2b\u8840\uff0828.1%\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u8ba1\u6570\u964d\u4f4e\u548c\u767d\u7ec6\u80de\u6570\u964d\u4f4e\uff08\u5747\u4e3a21.9%\uff09\u3001\u9ad8\u5c3f\u9178\u8840\u75c7\u548c\u8179\u6cfb\uff08\u5747\u4e3a15.6%\uff09\u3001\u9ad8\u78f7\u8840\u75c7\u548c\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff08\u5747\u4e3a12.5%\uff09\u30027\u4f8b\u53d7\u8bd5\u8005\u53d1\u751f\u4e863-4\u7ea7TRAE\uff0c\u5305\u62ec\u8840\u5c0f\u677f\u8ba1\u6570\u964d\u4f4e\uff0818.8%\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u8ba1\u6570\u964d\u4f4e\uff0812.5%\uff09\u3001\u767d\u7ec6\u80de\u6570\u964d\u4f4e\uff089.4%\uff09\u3001\u8d2b\u8840\uff086.3%\uff09\u30021\u4f8b\u53d7\u8bd5\u8005\u53d1\u751f2\u9879\u836f\u7269\u76f8\u5173\uff08\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff09SAE\uff0c\u5206\u522b\u4e3a\u8d2b\u8840\u548c\u8840\u5c0f\u677f\u8ba1\u6570\u51cf\u5c11\uff08\u5747\u4e3a3.1%\uff09\u3002 <\/li>\n
    • \u5171\u670925\u4f8b\u53d7\u8bd5\u8005\u81f3\u5c11\u5b8c\u6210\u4e86\u4e00\u6b21\u80bf\u7624\u8bc4\u4f30\uff0c\u5176\u4e2d9\u4f8b\u83b7\u5f97\u4e86CR\u6216PR\uff0c\u4e2d\u4f4d\u8d77\u6548\u65f6\u95f4\u4e3a2\u4e2a\u6cbb\u7597\u5468\u671f\u3002CLL\/SLL\u83b7\u5f97\u6700\u9ad8\u7f13\u89e3\u7387\uff0866.7%\uff09\uff0c\u63a5\u53d7200mg\u53ca\u5176\u4ee5\u4e0a\u5242\u91cflisaftoclax\u6cbb\u7597\u7684\u6240\u67096\u4f8bCLL\u53d7\u8bd5\u8005\u5747\u83b7\u76ca\uff0c\u5305\u62ec1\u4f8bCR\u548c5\u4f8bPR\u30022\u4f8bMZL\uff0866.7%\uff09\u548c1\u4f8bMCL\uff0825%\uff09\u83b7\u5f97PR\u30021\u4f8bMF\u53d7\u8bd5\u8005\u5728\u7ecf\u8fc71\u4e2a\u5468\u671flisaftoclax\u6cbb\u7597\u540e\uff0c\u76ae\u80a4\u80bf\u7624\u5305\u5757\u8868\u73b0\u51fa\u4e0d\u540c\u7a0b\u5ea6\u7684\u7f29\u5c0f\u3002100mg\u53ca\u5176\u4ee5\u4e0a\u5242\u91cf\u7ec4\u53ef\u89c2\u5bdf\u5230\u4e0d\u540c\u7a0b\u5ea6\u7684\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u503c\uff08ALC\uff09\u4e0b\u964d\u3002 <\/li>\n
    • \u521d\u6b65PK\u7ed3\u679c\u663e\u793alisaftoclax\u66b4\u9732\u91cf\u968f\u774020mg\u81f3800mg\u5242\u91cf\u6c34\u5e73\u7684\u589e\u52a0\u800c\u4e0d\u65ad\u589e\u9ad8\uff0c\u5e73\u5747\u534a\u8870\u671f\u4e3a4-6\u5c0f\u65f6\u3002lisaftoclax\u4f5c\u4e3aBH3\u7c7b\u4f3c\u7269\u80fd\u591f\u5feb\u901f\u89e6\u53d1CLL\/SLL\u53d7\u8bd5\u8005\u8840\u6807\u672c\u4e2dBCL-2\u590d\u5408\u7269\u53d8\u5316\uff0c\u4ece\u800c\u5feb\u901f\u964d\u4f4e\u60a3\u8005\u5916\u5468\u8840ALC\u6c34\u5e73\u3002 <\/li>\n
    • \u7ed3\u8bba\uff1alisaftoclax\u8010\u53d7\u6027\u826f\u597d\uff0c\u6bcf\u65e5\u53e3\u670d\u5242\u91cf\u6700\u9ad8\u53ef\u8fbe800mg\u3002\u5373\u4f7f\u662fTLS\u4e2d\u9ad8\u5371\u53d7\u8bd5\u8005\u63a5\u53d7\u6bcf\u65e5\u5242\u91cf\u9012\u589e\u7ed9\u836f\u65b9\u6848\u8fdb\u884c\u5feb\u901f\u722c\u5761\u81f3\u6cbb\u7597\u5242\u91cf\uff0c\u65e0\u4efb\u4f55TLS\u53d1\u751f\u3002\u4e0evenetoclax\u76f8\u6bd4\uff0c\u4ea6\u672a\u89c2\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u6216\u4e0d\u53ef\u63a7\u7684TRAE\u3002\u56e0\u6b64\uff0clisaftoclax\u4e3aR\/R HMs\u60a3\u8005\u63d0\u4f9b\u4e86\u4e00\u9879\u5b89\u5168\u4e14\u6709\u6548\u7684\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/li>\n<\/ul>\n<\/ul>\n

      Trial in Progress: Phase 1b<\/span> Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and\/or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (R\/R CLL\/SLL)<\/b><\/p>\n

      lisaftoclax (APG-2575)<\/b>\u5355\u836f\u6216\u8054\u5408\u6cbb\u7597\u590d\u53d1<\/b>\/<\/b>\u96be\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5<\/b>\/<\/b>\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08<\/b>R\/R CLL\/SLL<\/b>\uff09\u7684<\/b>Ib<\/b>\u671f\u4e34\u5e8a\u7814\u7a76<\/b><\/p>\n

        \n
      • \u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a <\/li>\n
      • \u6458\u8981\u7f16\u53f7\uff1a1554 <\/li>\n
      • \u5206\u4f1a\u573a\uff1a642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I\uff08\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u548c\u6d41\u884c\u75c5\u5b66\uff1a\u58c1\u62a5\u5c55\u793aI\uff09 <\/li>\n
      • \u6838\u5fc3\u8981\u70b9\uff1a <\/li>\n
          \n
        • \u8fd9\u662f\u4e00\u9879\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027Ib\u671f\u7814\u7a76\u3002\u8be5\u7814\u7a76\u5206\u4e3a\u4e24\u4e2a\u9636\u6bb5\uff0c\u7b2c\u4e00\u9636\u6bb5\u4e3alisaftoclax\u5355\u836f\u6cbb\u7597\uff0c\u7b2c\u4e8c\u9636\u6bb5\u4e3alisaftoclax\u8054\u5408\u6cbb\u7597\u9636\u6bb5\uff0c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u662f\u8bc4\u4f30\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 <\/li>\n
        • \u7b2c\u4e00\u9636\u6bb5\u91c7\u7528\u6807\u51c6\u76843+3\u722c\u5761\u8bbe\u8ba1\uff0clisaftoclax\u6bcf\u65e5\u53e3\u670d\u7ed9\u836f\uff0c\u8fde\u7eed28\u5929\u3002\u63a2\u7d22\u5242\u91cf\u5305\u62ec400mg\u3001600mg\u3001800mg\u3002\u4e3a\u4e86\u964d\u4f4eTLS\u7684\u98ce\u9669\uff0clisaftoclax\u91c7\u7528\u66f4\u4e3a\u4fbf\u5229\u7684\u6bcf\u65e5\u5242\u91cf\u68af\u5ea6\u9012\u589e\u7ed9\u836f\u65b9\u6848\u3002 <\/li>\n
        • \u7b2c\u4e8c\u9636\u6bb5\u4e3alisaftoclax\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u6216\u963f\u5361\u66ff\u5c3c\u76843+3\u722c\u5761\u8bbe\u8ba1\u7684\u5242\u91cf\u9012\u589e\u9636\u6bb5\uff0c\u4e4b\u540e\u5728RP2D\u4e0a\u8fdb\u884c\u6269\u5c55\u3002 <\/li>\n
        • \u622a\u6b622021\u5e747\u670819\u65e5\uff0c71\u4f8b\u60a3\u8005\u5b8c\u6210\u5165\u7ec4\uff08\u7814\u7a76\u8ba1\u5212\u7684\u5165\u7ec4\u603b\u4f8b\u6570\u4e3a144\u4f8b\uff09\u3002<\/li>\n<\/ul>\n<\/ul>\n

          APG-1252\u57282021 ASH\u5e74\u4f1a\u5c55\u793a\u7684\u7814\u7a76\u6570\u636e\u5982\u4e0b\uff1a<\/p>\n

          Antitumor Activity of Dual BCL-2\/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer\/T-Cell Lymphoma (NK\/TCL)<\/b><\/p>\n

          BCL-2\/BCL-xL<\/b>\u53cc\u9776\u70b9\u6291\u5236\u5242<\/b>pelcitoclax<\/b>\uff08<\/b>APG-1252<\/b>\uff09\u7684\u6297\u81ea\u7136\u6740\u4f24<\/b>\/T<\/b>\u7ec6\u80de\u6dcb\u5df4\u7624\uff08<\/b>NK\/TCL<\/b>\uff09\u6d3b\u6027<\/b><\/p>\n

            \n
          • \u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a <\/li>\n
          • \u6458\u8981\u7f16\u53f7\uff1a2062 <\/li>\n
          • \u5206\u4f1a\u573a\uff1a203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II \uff08\u6dcb\u5df4\u7ec6\u80de\u548c\u5148\u5929\u6027\u6216\u83b7\u5f97\u6027\u514d\u75ab\u7f3a\u9677\uff1a\u58c1\u62a5\u5c55\u793aII\uff09 <\/li>\n
          • \u6838\u5fc3\u8981\u70b9\uff1a <\/li>\n
              \n
            • \u8fd9\u662f\u4e00\u9879\u65e8\u5728\u8bc4\u4f30APG-1252\u5728NK\/TCL\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6f5c\u5728\u6297\u80bf\u7624\u4f5c\u7528\u7684\u7814\u7a76\u3002\u57fa\u4e8e\u7ec6\u80de\u7684\u6297\u589e\u6b96\u7814\u7a76\u663e\u793a\uff0cAPG-1252\u53ca\u5176\u66f4\u6709\u6548\u7684\u4ee3\u8c22\u7269APG-1252-M1\u5bf9\u8fc7\u8868\u8fbeBCL-xL\u7684NK\/TCL\u7ec6\u80de\u7cfb\u6709\u6297\u589e\u6b96\u6d3b\u6027\u3002APG-1252\u5728SNK-1\u3001SNK-6\u548cSNK-8\uff08EBV\u9633\u6027NK\/TCL\uff09\u7ec6\u80de\u7cfb\u4e2dIC50\u5206\u522b\u4e3a2.652±2.606\u03bcM\u30011.568±1.109\u03bcM\u548c0.557±0.383\u03bcM\u3002APG-1252-M1\u7684\u76f8\u5e94IC50\u5206\u522b\u4e3a0.133±0.056\u03bcM\u30010.064±0.014\u03bcM\u548c0.020±0.008\u03bcM\u3002 <\/li>\n
            • \u673a\u7406\u7814\u7a76\u8868\u660e\uff0cAPG-1252\u548cAPG-1252-M1\u7834\u574f\u4e86SNK-6\u7ec6\u80de\u4e2dBCL-XL\u4e0eBAX\u6216BAK\u7684\u590d\u5408\u7269\uff0c\u4ece\u800c\u91ca\u653e\u8fd9\u4e9b\u4fc3\u51cb\u4ea1\u86cb\u767d\uff0c\u5e76\u901a\u8fc7\u5207\u5272PARP-1\u548ccaspase-3\u8fdb\u4e00\u6b65\u6fc0\u6d3b\u4e0b\u6e38\u51cb\u4ea1\u9014\u5f84\u3002\u5728SNK-6\u5f02\u79cd\u79fb\u690d\u6a21\u578b\u4e2d\uff0c\u4ee5\u6bcf\u5468\u4e24\u6b2165mg\/kg\u6216\u6bcf\u5468\u4e00\u6b21100mg\/kg\u7ed9\u836f\uff0cAPG-1252\u8868\u73b0\u51fa\u663e\u7740\u7684\u6297\u80bf\u7624\u4f5c\u7528\uff0c\u80bf\u7624\u751f\u957f\u901f\u7387\uff08T\/C%\uff09\u4e3a13.7%\u81f330.7%\u3002 <\/li>\n
            • \u6b64\u5916\uff0cAPG-1252\u4e0eHDAC\u6291\u5236\u5242\u897f\u8fbe\u672c\u80fa\u6216DDGP\uff08\u5730\u585e\u7c73\u677e\u3001\u987a\u94c2\u3001\u5409\u897f\u4ed6\u6ee8\u548c\u95e8\u51ac\u9170\u80fa\u9176\uff09\u7684\u5316\u7597\u7ec4\u5408\u8054\u7528\u663e\u793a\u51fa\u534f\u540c\u6548\u5e94\u3002\u5c0f\u9f20\u836f\u4ee3\u52a8\u529b\u5b66\u8bc4\u4f30\u663e\u793aAPG-1252\u5728\u8840\u6d46\u548c\u80bf\u7624\u7ec4\u7ec7\u4e2d\u5177\u6709\u8f83\u957f\u534a\u8870\u671f\uff0c\u5206\u522b\u4e3a127\u5c0f\u65f6\u548c25.2\u5c0f\u65f6\u3002\u91cd\u8981\u7684\u662f\uff0cAPG-1252\u7ed9\u836f\u540e\uff0c\u80bf\u7624\u7ec4\u7ec7\u4e2dAPG-1252\u5411APG-1252-M1\u7684\u8f6c\u5316\u7387\u6bd4\u8840\u6d46\u4e2d\u7684\u8f6c\u5316\u7387\u9ad816\u500d\uff0822%\u5bf91.3%\uff09\uff0c\u63d0\u793aAPG-1252\u53ef\u964d\u4f4e\u8840\u6d46\u4e2dAPG-1252-M1\u5f15\u8d77\u7684\u8840\u5c0f\u677f\u6bd2\u6027\u3002 <\/li>\n
            • \u7ed3\u8bba\uff1a\u65e0\u8bba\u662f\u4f5c\u4e3a\u5355\u4e00\u836f\u7269\u8fd8\u662f\u4e0eHDAC\u6291\u5236\u5242\u6216\u5316\u7597\u8054\u5408\uff0cAPG-1252\u5728NK\/TCL\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u80bf\u7624\u4f5c\u7528\u3002\u8fd9\u4e9b\u53d1\u73b0\u4e3a\u8fdb\u4e00\u6b65\u8bc4\u4f30APG-1252\u4f5c\u4e3aNK\/TCL\u7684\u6f5c\u5728\u6cbb\u7597\u65b9\u6848\u63d0\u4f9b\u4e86\u8bc1\u636e\u3002<\/li>\n<\/ul>\n<\/ul>\n

              \u5173\u4e8e\u4e9a\u76db\u533b\u836f\uff08<\/u><\/b>6855.HK<\/u><\/b>\uff09<\/u><\/b><\/p>\n

              \u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n

              \u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67098\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b®<\/sup>\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5ba1\u8bc4\u5feb\u901f\u901a\u9053\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9712\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879\u201c\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730\u201d\u53ca4\u9879\u201c\u521b\u65b0\u836f\u7269\u7814\u53d1\u201d\uff0c\u53e6\u5916\u627f\u62c5\u201c\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb\u201d\u4e13\u98791\u9879\u3002<\/p>\n

              \u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c\u201c\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u201d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

              \u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n

              \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n

              <\/div>\n

              \u76f8\u5173\u94fe\u63a5 :<\/p>\n

              A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions<\/a><\/p><\/blockquote>\n